CN Patent

CN105164261B — 用于增强的细胞摄取的化合物和方法

Assigned to Regulus Therapeutics Inc · Expires 2022-03-18 · 4y expired

What this patent protects

在此描述了与靶RNA互补的缀合的修饰的寡核苷酸。该缀合物促进该修饰的寡核苷酸的细胞摄取，从而引起提高的效力。

USPTO Abstract

在此描述了与靶RNA互补的缀合的修饰的寡核苷酸。该缀合物促进该修饰的寡核苷酸的细胞摄取，从而引起提高的效力。

Drugs covered by this patent

eplontersen-sodium (EPLONTERSEN SODIUM)

Patent Metadata

Patent number: CN105164261B
Jurisdiction: CN
Classification: —
Expires: 2022-03-18
Drug substance claim: No
Drug product claim: No
Assignee: Regulus Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.